Inhalation Aromatherapy for Patients Undergoing Conservative Sharp Wound Debridement:
The Effectiveness and Acceptability of Inhalation Aromatherapy for Patients Undergoing Conservative Sharp Wound Debridement: A Pilot Randomized Controlled Trial
The goal of this pilot clinical trial is to learn if inhalation aromatherapy works to reduce anxiety and pain in patients with venous leg ulcers undergoing conservative sharp wound debridement (CSWD). It will also learn about the feasibility of implementing this intervention in clinical practice. The main questions it aims to answer are:
Does inhalation aromatherapy reduce anxiety levels during CSWD procedures, as measured by STAI-S scores? Does inhalation aromatherapy reduce pain intensity during CSWD procedures? Is inhalation aromatherapy feasible and acceptable to implement in a clinical setting? What are the protocol adherence rates and potential areas of missing data?
Researchers will compare inhalation aromatherapy using Asian essential oil extracts to standard care to see if aromatherapy works to reduce anxiety and pain during wound debridement.
Participants will:
Receive either inhalation aromatherapy or standard care during their CSWD procedure Complete State-Trait Anxiety Inventory (STAI-S) questionnaires before and after the procedure Rate their pain intensity using visual analog scales during the debridement Provide feedback on treatment satisfaction and acceptability Attend clinic visits for wound debridement as part of their standard care
This pilot study hypothesizes that inhalation aromatherapy is feasible and acceptable to implement in a clinical setting and may be associated with differences in anxiety and pain intensity during CSWD, compared to standard care
調査の概要
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Nanthakumahrie Gunasegaran
- 電話番号:+65 97250435
- メール:nanthakumahrie.gunasegaran@sgh.com.sg
研究場所
-
-
-
Singapore、シンガポール、Singapore
- 募集
- Singapore General Hospital
-
コンタクト:
- Singapore General Hospital Singapore General Hospital
- 電話番号:+65 65762590
- メール:nursing.research@sgh.com.sg
-
-
参加基準
適格基準
就学可能な年齢
- 大人
健康ボランティアの受け入れ
説明
Inclusion Criteria:
-≥21 years old
-Venous leg ulcers requiring conservative sharp wound debridement
Exclusion Criteria:
- Known sensitivity or hypersensitivity to essential oils or any components in the Aromatherapy scent formulation
- Allergic rhinitis, asthma, chronic lung disease or any disease that impairs the sense of smell
- Airway hypersensitivity to fragrances, paint/gasoline fumes or turpentine
- Using aromatherapy of any kind
- Taking any anti-psychotic drugs
- Incapable of providing verbal/written consent
- On anti-anxiety medications
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:支持療法
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Inhalation Aromatherapy- Intervention group
Participants allocated to the intervention group receive a personal nasal inhalation stick infused with a blend of Asian aromatic plant extracts formulated by a qualified aromatherapist, selected based on known anxiolytic and analgesic pharmacological properties.
The final blend is determined through a scent preference evaluation conducted with five VLU patient volunteers prior to the main study.
Participants inhale the stick for 5 minutes before entering the clinic room and continue using it throughout the CSWD procedure for up to 10 minutes or until the procedure is completed, inhaling at least twice in each nostril prior to the procedure.
Aromatherapy works through positive olfactory effects and direct modulation of the amygdala via the olfactory nerve, potentially reducing anxiety and enhancing comfort during the procedure.
Each participant is issued their own inhalation stick for personal use across all study visits to maintain hygiene and ensure consistent dosing.
|
Patients are allocated to either the Inhalation Aromatherapy or Inhalation Placebo group in a 1:1 ratio via randomly permuted block randomization.
The randomization sequence is generated by a non-study member using a computer-generated program.
Allocation concealment is maintained through the use of sequentially numbered, opaque, sealed envelopes to prevent selection .
Inhalation aromatherapy intervention an inhalation stick containing a blend of Asian aromatic plant extracts, including Basil, Elemi, and Calamansi, specifically selected for their pharmacological properties in alleviating anxiety, agitation, stress, and pain.
Unlike conventional pharmacological interventions, the dose is not fixed but individually determined by the frequency of inhalation, varying based on individual pharmacokinetics and personal response to the aroma.
Patients inhale at least twice, once in each nostril, beginning five minutes before the procedure and continuing throughout CSWD for up to ten minutes.
|
|
プラセボコンパレーター:Inhalation Placebo-Control group
Participants allocated to the control group receive a personal nasal inhalation stick identical in appearance, size, and packaging to the intervention stick, containing certified organic jojoba carrier oil with no known anxiolytic properties.
Jojoba oil has a barely perceptible, slightly sweet aroma and is widely used in aromatherapy blends.
Participants follow an identical inhalation protocol to the intervention group, inhaling for 5 minutes before the procedure and continuing throughout CSWD for up to 10 minutes or until the procedure is completed.
This ensures that any non-specific effects of the inhalation ritual, including focused breathing and expectation of benefit, are equally present in both arms, thereby isolating the specific pharmacological effect of the aromatic compounds.
|
Patients are allocated to either the Inhalation Aromatherapy or Inhalation Placebo group in a 1:1 ratio via randomly permuted block randomization.
The randomization sequence is generated by a non-study member using a computer-generated program.
Allocation concealment is maintained through the use of sequentially numbered, opaque, sealed envelopes to prevent selection .
Inhalation aromatherapy intervention an inhalation stick containing a blend of Asian aromatic plant extracts, including Basil, Elemi, and Calamansi, specifically selected for their pharmacological properties in alleviating anxiety, agitation, stress, and pain.
Unlike conventional pharmacological interventions, the dose is not fixed but individually determined by the frequency of inhalation, varying based on individual pharmacokinetics and personal response to the aroma.
Patients inhale at least twice, once in each nostril, beginning five minutes before the procedure and continuing throughout CSWD for up to ten minutes.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Participation Rate
時間枠:Throughout the 12-month data collection period from October 2026 to September 2027.
|
The number of recruited patients divided by total eligible patients approached, expressed as a percentage.
|
Throughout the 12-month data collection period from October 2026 to September 2027.
|
|
Retention rate
時間枠:The number of participants completed 3rd clinic visit/15th day, across the 12-month data collection period from October 2026 to September 2027. Clinic visit 1 - 1st Day- week 1, Clinic visit 2 -8th Day- week 2, Clinic visit 3- 15th Day- week 3.
|
The number of patients remaining divided by total patients who consented, expressed as a percentage.
|
The number of participants completed 3rd clinic visit/15th day, across the 12-month data collection period from October 2026 to September 2027. Clinic visit 1 - 1st Day- week 1, Clinic visit 2 -8th Day- week 2, Clinic visit 3- 15th Day- week 3.
|
|
Percentage Change in State Anxiety Level During Conservative Sharp Wound Debridement
時間枠:Completed at 3rd clinic visit/15th day, across the 12-month data collection period from October 2026 to September 2027. Clinic visit 1 - 1st Day- week 1, Clinic visit 2 -8th Day- week 2, Clinic visit 3- 15th Day- week 3
|
Percentage change in STAI-S score at T1 (2nd clinic visit/2nd week/8th day): (pre-CSWD STAI-S minus post-CSWD STAI-S) divided by pre-CSWD STAI-S, multiplied by 100. Unit: percentage change on STAI-S scale. Percentage change in STAI-S score at T2 (3rd clinic visit/3rd week/15th Day), calculated. Unit: percentage change on STAI-S scale. Reported separately to assess sustainability of effect over time. |
Completed at 3rd clinic visit/15th day, across the 12-month data collection period from October 2026 to September 2027. Clinic visit 1 - 1st Day- week 1, Clinic visit 2 -8th Day- week 2, Clinic visit 3- 15th Day- week 3
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Protocol Adherence Rate
時間枠:Assessed throughout the 12-month data collection period from October 2026 to September 2027.
|
Protocol adherence, which is given by the proportion of patients correctly receiving the allocated treatment out of all patients who consented to the study.
|
Assessed throughout the 12-month data collection period from October 2026 to September 2027.
|
|
Attrition Rate and Extent of Missing Data
時間枠:Assessed through the 12-month data collection period from October 2026 to September 2027. Clinic visit 1 - 1st Day- week 1, Clinic visit 2 -8th Day- week 2, Clinic visit 3- 15th Day- week 3.
|
Attrition rates (withdrawal or loss-to-follow-up as compared to completion of all 3 clinic visits)
|
Assessed through the 12-month data collection period from October 2026 to September 2027. Clinic visit 1 - 1st Day- week 1, Clinic visit 2 -8th Day- week 2, Clinic visit 3- 15th Day- week 3.
|
|
Change in Pain Intensity During Conservative Sharp Wound Debridement
時間枠:Change in pain intensity measured pre- and post-CSWD at T1 (2nd Clinic visit/8th Day) and T2 (3rd Clinic visit/15th Day) to assess sustainability, using (VAS), scored 0-100mm. Clinic visit 2 -8th Day- week 2, Clinic visit 3 -15th Day -week3.
|
Change in pain intensity during CSWD, which is given by the difference in VAS score before and after CSWD
|
Change in pain intensity measured pre- and post-CSWD at T1 (2nd Clinic visit/8th Day) and T2 (3rd Clinic visit/15th Day) to assess sustainability, using (VAS), scored 0-100mm. Clinic visit 2 -8th Day- week 2, Clinic visit 3 -15th Day -week3.
|
協力者と研究者
出版物と役立つリンク
一般刊行物
- Sun X, Jiang K, Chen J, Wu L, Lu H, Wang A, Wang J. A systematic review of maggot debridement therapy for chronically infected wounds and ulcers. Int J Infect Dis. 2014 Aug;25:32-7. doi: 10.1016/j.ijid.2014.03.1397. Epub 2014 May 16.
- Kiecolt-Glaser JK, Marucha PT, Malarkey WB, Mercado AM, Glaser R. Slowing of wound healing by psychological stress. Lancet. 1995 Nov 4;346(8984):1194-6. doi: 10.1016/s0140-6736(95)92899-5.
- Schultz GS, Sibbald RG, Falanga V, Ayello EA, Dowsett C, Harding K, Romanelli M, Stacey MC, Teot L, Vanscheidt W. Wound bed preparation: a systematic approach to wound management. Wound Repair Regen. 2003 Mar;11 Suppl 1:S1-28. doi: 10.1046/j.1524-475x.11.s2.1.x.
- Malone M, Bjarnsholt T, McBain AJ, James GA, Stoodley P, Leaper D, Tachi M, Schultz G, Swanson T, Wolcott RD. The prevalence of biofilms in chronic wounds: a systematic review and meta-analysis of published data. J Wound Care. 2017 Jan 2;26(1):20-25. doi: 10.12968/jowc.2017.26.1.20.
- Zhang N, Yao L. Anxiolytic Effect of Essential Oils and Their Constituents: A Review. J Agric Food Chem. 2019 Dec 18;67(50):13790-13808. doi: 10.1021/acs.jafc.9b00433. Epub 2019 Jun 13.
- Hedigan F, Sheridan H, Sasse A. Benefit of inhalation aromatherapy as a complementary treatment for stress and anxiety in a clinical setting - A systematic review. Complement Ther Clin Pract. 2023 Aug;52:101750. doi: 10.1016/j.ctcp.2023.101750. Epub 2023 Apr 5.
- Rohi Ganji M, Jafari F, Rezaeian S, Abdi H, Farzaei MH, Khatony A. The Effect of Inhalation Aromatherapy and Music Therapy on Anxiety in Patients Undergoing Shockwave Lithotripsy: A Randomized Controlled Clinical Trial. Evid Based Complement Alternat Med. 2022 Jun 29;2022:8015798. doi: 10.1155/2022/8015798. eCollection 2022.
- RETRACTION: The Role of Orthobiologics in Chronic Wound Healing. Int Wound J. 2025 Aug;22(8):e70744. doi: 10.1111/iwj.70744.
- Liu YF, Ni PW, Huang Y, Xie T. Therapeutic strategies for chronic wound infection. Chin J Traumatol. 2022 Jan;25(1):11-16. doi: 10.1016/j.cjtee.2021.07.004. Epub 2021 Jul 6.
- James KA, Stromin JI, Steenkamp N, Combrinck MI. Understanding the relationships between physiological and psychosocial stress, cortisol and cognition. Front Endocrinol (Lausanne). 2023 Mar 6;14:1085950. doi: 10.3389/fendo.2023.1085950. eCollection 2023.
- Thomas DC, Tsu CL, Nain RA, Arsat N, Fun SS, Sahid Nik Lah NA. The role of debridement in wound bed preparation in chronic wound: A narrative review. Ann Med Surg (Lond). 2021 Oct 4;71:102876. doi: 10.1016/j.amsu.2021.102876. eCollection 2021 Nov.
- Cui J, Li M, Wei Y, Li H, He X, Yang Q, Li Z, Duan J, Wu Z, Chen Q, Chen B, Li G, Ming X, Xiong L, Qin D. Inhalation Aromatherapy via Brain-Targeted Nasal Delivery: Natural Volatiles or Essential Oils on Mood Disorders. Front Pharmacol. 2022 Apr 12;13:860043. doi: 10.3389/fphar.2022.860043. eCollection 2022.
- Fiala CA, Abbott LI, Carter CD, Hillis SL, Wolf JS, Schuster M, Dulski R, Grice EA, Rakel BA, Gardner SE. Severe pain during wound care procedures: A cross-sectional study protocol. J Adv Nurs. 2018 May 7:10.1111/jan.13699. doi: 10.1111/jan.13699. Online ahead of print.
- Matsuzaki K, Upton D. Wound treatment and pain management: a stressful time. Int Wound J. 2013 Dec;10(6):638-44. doi: 10.1111/j.1742-481X.2012.01038.x. Epub 2012 Aug 21.
- Woo KY. Chronic wound-associated pain, psychological stress, and wound healing. Surg Technol Int. 2012 Dec;22:57-65.
- Brown A. The assessment and treatment of wound pain. Nurs Times. 2015 Nov 18-24;111(47):15-7.
- McGuire L, Heffner K, Glaser R, Needleman B, Malarkey W, Dickinson S, Lemeshow S, Cook C, Muscarella P, Melvin WS, Ellison EC, Kiecolt-Glaser JK. Pain and wound healing in surgical patients. Ann Behav Med. 2006 Apr;31(2):165-72. doi: 10.1207/s15324796abm3102_8.
- Briggs M, Nelson EA, Martyn-St James M. Topical agents or dressings for pain in venous leg ulcers. Cochrane Database Syst Rev. 2012 Nov 14;11(11):CD001177. doi: 10.1002/14651858.CD001177.pub3.
- Gardner SE, Abbott LI, Fiala CA, Rakel BA. Factors associated with high pain intensity during wound care procedures: A model. Wound Repair Regen. 2017 Aug;25(4):558-563. doi: 10.1111/wrr.12553. Epub 2017 Aug 14.
- Rodd-Nielsen E, Harris CL. Conservative sharp wound debridement: an overview of Canadian education, practice, risk, and policy. J Wound Ostomy Continence Nurs. 2013 Nov-Dec;40(6):594-601. doi: 10.1097/WON.0b013e3182a9ae8c.
- Tian X, Liang XM, Song GM, Zhao Y, Yang XL. Maggot debridement therapy for the treatment of diabetic foot ulcers: a meta-analysis. J Wound Care. 2013 Sep;22(9):462-9. doi: 10.12968/jowc.2013.22.9.462.
- Anghel EL, DeFazio MV, Barker JC, Janis JE, Attinger CE. Current Concepts in Debridement: Science and Strategies. Plast Reconstr Surg. 2016 Sep;138(3 Suppl):82S-93S. doi: 10.1097/PRS.0000000000002651.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- ECOS Ref.: 2026-0326
- AM/SU120/2026 (SRDUKAMR26S0) (その他の助成金/資金番号:SingHealth Duke-NUS Academic Medicine Research Grant 2.0 FY2026)
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。